These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25761745)

  • 1. Usability of prostaglandin monotherapy eye droppers.
    Drew T; Wolffsohn JS
    Br J Ophthalmol; 2015 Sep; 99(9):1251-4. PubMed ID: 25761745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects.
    Kawai-Tsuboi N; Kawai M; Minami Y; Yoshida A
    J Glaucoma; 2015 Mar; 24(3):202-6. PubMed ID: 23807351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
    Robin AL; Covert D
    Ophthalmology; 2005 May; 112(5):863-8. PubMed ID: 15878067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.
    Garway-Heath DF; Crabb DP; Bunce C; Lascaratos G; Amalfitano F; Anand N; Azuara-Blanco A; Bourne RR; Broadway DC; Cunliffe IA; Diamond JP; Fraser SG; Ho TA; Martin KR; McNaught AI; Negi A; Patel K; Russell RA; Shah A; Spry PG; Suzuki K; White ET; Wormald RP; Xing W; Zeyen TG
    Lancet; 2015 Apr; 385(9975):1295-304. PubMed ID: 25533656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current trend of glaucoma medication with various eye drops].
    Fukuchi T
    Nippon Ganka Gakkai Zasshi; 2013 Oct; 117(10):781-3. PubMed ID: 24354261
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of long-term topical prostaglandin therapy on central corneal thickness.
    Maruyama Y; Mori K; Ikeda Y; Ueno M; Kinoshita S
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):440-4. PubMed ID: 24738848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating eye drop instillation technique in glaucoma patients.
    Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
    J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
    Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of latanoprost when stored at room temperature.
    Mochizuki H; Itakura H; Takamatsu M; Kiuchi Y
    Hiroshima J Med Sci; 2008 Jun; 57(2):69-72. PubMed ID: 18717189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of discontinuation and change of glaucoma therapy in a managed care setting.
    Spooner JJ; Bullano MF; Ikeda LI; Cockerham TR; Waugh WJ; Johnson T; Mozaffari E
    Am J Manag Care; 2002 Aug; 8(10 Suppl):S262-70. PubMed ID: 12188169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a short version of the glaucoma medication self-efficacy questionnaire.
    Sleath B; Blalock SJ; Stone JL; Skinner AC; Covert D; Muir K; Robin AL
    Br J Ophthalmol; 2012 Feb; 96(2):258-62. PubMed ID: 21610264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
    Kozobolis VP; Detorakis ET; Maskaleris G; Koukoula SC; Fountoulakis N; Chrysochoou F; Konstas AG
    Am J Ophthalmol; 2005 Apr; 139(4):742-3. PubMed ID: 15808188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.